IKS-03 by Iksuda Therapeutics for Diffuse Large B-Cell Lymphoma: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

IKS-03 overview

IKS-03 (LCB-73, NI-2201) is under development for the treatment of acute lymphocytic leukemia, Burkitt lymphoma, diffuse large B-cell lymphoma, chronic lymphocytic leukemia (CLL), follicular lymphoma, mantle cell lymphoma and b-cell non-Hodgkin lymphoma. It acts by targeting CD19. The therapeutic candidate is an antibody-drug conjugate (ADC). It is being developed based on ConjuALL platform technology.

Iksuda Therapeutics overview

Iksuda Therapeutics (Iksuda), formerly Glythera is a biotechnology company that focuses on the development of antibody drug conjugates (ADCs) and biotherapeutics for the treatment of cancer. The company develops antibody-based therapies for the treatment of cancer and broader based therapeutics. It uses its proprietary linker and stable glycan technologies permalink and premacarb to deliver solutions for development and manufacture efficacious and safe biologics to improve half-life and optimize bio-availability. The company partners with various biotech companies for its technology development activities. Iksuda is headquartered in Newcastle upon Tyne, Tyne and Wear, the UK.

For a complete picture of IKS-03’s drug-specific PTSR and LoA scores, buy the report here.